These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 11287843)

  • 1. Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.
    Raevens S; Fallon MB
    Hepatology; 2018 Nov; 68(5):2016-2028. PubMed ID: 29729196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatopulmonary Syndrome.
    Lv Y; Fan D
    Dig Dis Sci; 2015 Jul; 60(7):1914-23. PubMed ID: 25732713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment for hepatopulmonary syndrome.
    Eshraghian A; Kamyab AA; Yoon SK
    Biomed Res Int; 2013; 2013():670139. PubMed ID: 24102057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylene blue improves the hepatopulmonary syndrome.
    Groneberg DA; Fischer A
    Ann Intern Med; 2001 Sep; 135(5):380-1. PubMed ID: 11529704
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined treatment with a nonselective nitric oxide synthase inhibitor (l-NMMA) and indomethacin increases ductus constriction in extremely premature newborns.
    Keller RL; Tacy TA; Fields S; Ofenstein JP; Aranda JV; Clyman RI
    Pediatr Res; 2005 Dec; 58(6):1216-21. PubMed ID: 16306196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibition of nitric oxide synthase has an analgesic effect in chronic pain].
    Ashina M; Lassen LH; Bendtsen L; Jensen RA; Olesen J
    Ugeskr Laeger; 2000 Jan; 162(2):171-3. PubMed ID: 10647315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylene blue and cirrhosis: pathophysiologic insights, therapeutic dilemmas.
    Fallon MB
    Ann Intern Med; 2000 Nov; 133(9):738-40. PubMed ID: 11074907
    [No Abstract]   [Full Text] [Related]  

  • 8. Nitric oxide synthase (NOS) inhibitors ameliorate retinal damage induced by ischemia in rats.
    Lam TT; Tso MO
    Res Commun Mol Pathol Pharmacol; 1996 Jun; 92(3):329-40. PubMed ID: 8827830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an NO-synthase inhibitor L-NMMA in the hepatopulmonary syndrome.
    Maniscalco M; Sofia M; Higenbottam T
    Respiration; 2001; 68(2):226. PubMed ID: 11287843
    [No Abstract]   [Full Text] [Related]  

  • 10. The hepatopulmonary syndrome: NO way out?
    Dinh-Xuan AT; Naeije R
    Eur Respir J; 2004 May; 23(5):661-2. PubMed ID: 15176675
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hepatopulmonary syndrome].
    Thevenot T; Pastor CM; Cervoni JP; Jacquelinet C; Nguyen-Khac E; Richou C; Heyd B; Vanlemmens C; Mantion G; Di Martino V; Cadranel J
    Gastroenterol Clin Biol; 2009; 33(6-7):565-79. PubMed ID: 19481392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nuances of NO synthase regulation in sepsis: Could targeting BH4 be the answer?
    Sand CA; Hobbs AJ
    Vascul Pharmacol; 2016 Feb; 77():35-7. PubMed ID: 26556765
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.